TPM3 and non-small cell lung carcinoma: However, ROS1 fusion partners showed diverse pattern in NSCLC in both our and MSKCC cohort, with CD74 being the most common partner, followed by EZR, SDC4, TPM3, and SLC34A2, indicating patients with ROS1 fusions represent a heterogeneous NSCLC group.